Rejected at 2:20 a.m. Nov, 01, 2023 ] by Ahmed7
Author: mfahhoum
Related Note: 1488847733019 1
Rationale for change

clopidogrel is an ADP receptor inhibitor, and ADP receptor inhibitors block P2Y12.

Rejection reason

comments

Text Text
First Aid First Aid
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
Sketchy
Sketchy 2
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#UWorld::COMLEX::24937 #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::06_Platelets::05_Antiplatelet_Medications #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::08_Glycoprotein_IIb/IIIa_Inhibitors #AK_Step2_v12::#SketchyIM::01_Cardiology::01_Ischemic_Heart_Disease::09_Post_ACS_Management #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::06_Antiplatelet_Drugs::Extra #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::03_Physiology::04_Thrombogenesis #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::06_Antiplatelets::*ADP_receptor_Inhibitors #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::03_Antiplatelet_agents #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::02_Platelet_Activation #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::04_Antiplatelet_Drugs::Extra #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::01_Bleeding_&_Clotting_Disorders::02_Bleeding_Disorders:_Platelet_Disorders_DDx #AK_Step1_v12::#UWorld::Step::1828 #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::06_ADP_Receptor_Inhibitors #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Step1_v12::#AMBOSS::T-069i #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::03_Mixing_Studies,_Ristocetin,_and_D-dimer #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step2_v12::#B&B::02_Cardio::02_Ischemic_Heart_Disease::02_STEMI::Extra